Plasma and lung concentrations of terbinafine: A pilot study

GIMT - Giornale Italiano delle Malattie del Torace

Volumn 60, Issue 4, 2006, Pages 235-240

  Schiraldi, G ^a   Della Patrona, S ^b   Colombo, M D ^c   Ravini, M C ^a   Bianchi, M ^a   Sabolla, L ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c Dipartimento Medico e Laboratorio Bioanalitico   (Italy)

Author keywords

Antifungal; Aspergillus; Gas chromatography; Mass spectrometry; Pulmonary infection; Terbinaflne

Indexed keywords

TERBINAFINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ASPERGILLUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHYTE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FEMALE; FUNGUS GROWTH; GAS CHROMATOGRAPHY; GROWTH INHIBITION; HUMAN; LUNG MYCOSIS; LUNG PARENCHYMA; LUNG RESECTION; MALE; MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PATHOGENESIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 33846539781     PISSN: 11270810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Schiraldi GF, Gramegna G, De Rosa C, et al. Chronic pulmonary aspergillosis: current classification and therapy. Curr Opin Investig Drugs 2003 Feb; 4: 186-91.
2. Schiraldi GF Colombo MD. Potential use of terbinafine in the treatment of aspergillosis. Rev Contemp Pharmacother 1997; 8: 349-56.
3. Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. In: Focus on Terbinafine, Drugs 1992; 43: 259-84.
4. Clayton YM. The in Vitro Activity of Terbinafine against uncommon Fungal Pathogens. In: Recent Trends in the Discovery, Development and Evaluation of Antifungal agents In: RA Fromtling, eds, Barcelona: Prous Science Publishers 1987: 433-9.
5. Schatz F. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20: 377-83.
6. Stephens A, Czok R, Male O. Terbinafine: Initial Clinical Results. In: Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. RA Fromtling, eds, Barcelona: Prous Science Publishers 1987: 511-20.
7. Schuster I, Schaude M, Schatz F et al. Preclinical Characteristics of Allylamines. In: Sterol Biosynthesis Inhibitors: Pharmaceutical and Agrochemical Aspects. Berg D, Plempel M eds, Chichester; Ellis Horwood Ltd/Weinheim; VCH Verlagsgesellschaft mbH Publishers 1988: 449-70.
8. Jensen JC. Pharmacokinetics of Lamisil® in humans. J Dermatol Treat 1990; Suppl 1: 29-32.
9. Schiraldi GF, Colombo MD, Harari S et al. Terbinafine in the treatment of non immunocompromised compassionate cases of bronchopulmonary aspergillosis. Mycoses 1996; 39: 5-12.
10. Harari S, Schiraldi GF, De Juli E, Gronda E. Relapsing aspergillus bronchitis in a double lung transplant patient, successfully treated with a new oral antimycotic agent. Chest 1997; 111: 835-6.
11. Denouël J, Schaub HP, Delaborde C, Humbert H. Determination of terbinafine and its desmethyl metabolite in human plasma by high performance liquid chromatography. J Chromatogr B 1995; 663: 357-9.
12. Zehender, H, Denouël J, Roy M, Le Saux L, and Schaub P. Simultaneous determination of terbinafine (Lamisil) and five metabolites in human plasma and urine by high performance liquid chromatography using on-line solid-phase extraction. J Chromatogr B 1995; 664: 347-55.